GURUFOCUS.COM » STOCK LIST » USA » NAS » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Stock Based Compensation
Switch to:

ALX Oncology Holdings (NAS:ALXO) Stock Based Compensation

: $23.85 Mil (TTM As of Dec. 2022)
View and export this data going back to 2020. Start your Free Trial

ALX Oncology Holdings's Stock Based Compensation for the three months ended in Dec. 2022 was $6.30 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2022 was $23.85 Mil.


ALX Oncology Holdings Stock Based Compensation Historical Data

The historical data trend for ALX Oncology Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
0.27 0.30 5.44 13.91 23.84

ALX Oncology Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Stock Based Compensation Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.69 5.50 5.84 6.21 6.30

ALX Oncology Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.85 Mil.


ALX Oncology Holdings Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


ALX Oncology Holdings (NAS:ALXO) Business Description

ALX Oncology Holdings logo
Traded in Other Exchanges
N/A
Address
323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Executives
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas director C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Shelly Pinto officer: VP, Finance and CAO 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Michael A Carusi 10 percent owner 1000 WINTER STREET, SUITE 3700, WALTHAM MA 02451
Venbio Global Strategic Gp Ii, Ltd. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Plain Henry A Jr 10 percent owner 125 CONSTITUTION DRIVE, MENLO PARK CA 94025-1118
Lightstone Ventures, L.p. 10 percent owner 500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lightstone Ventures (a), L.p. 10 percent owner 500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lsv Associates, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
Jason Lettmann director, 10 percent owner C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lightstone Ventures Ii, L.p. 10 percent owner 500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Lightstone Ventures Ii (a), L.p. 10 percent owner 500 BOYLSTON STREET, SUITE 1380, BOSTON MA 02116
Jaume Pons director, officer: President and CEO C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010

ALX Oncology Holdings (NAS:ALXO) Headlines

Other Sources